@inbook{fce1eb8a07d94af7896176434a9f6801,
title = "Arthritis Associated with Immune Checkpoint Inhibitors",
abstract = "The development and approval of immune checkpoint inhibitors (ICIs) have dramatically improved the outcomes for many cancer patients. However, these agents have unique toxicities known as immune-related adverse events (irAEs), which result from unpredictable activation of the immune system against host organs. A wide myriad of musculoskeletal and rheumatologic irAEs have been reported, but inflammatory arthritis remains the most frequent. Here, we will highlight the current state of knowledge about the epidemiology, pathogenesis, salient clinical presentations, and treatment strategies of ICI-induced inflammatory arthritis.",
keywords = "Arthritis, Cancer, Immune checkpoint inhibitors, Immune-related adverse events",
author = "Noha Abdel-Wahab and Suarez-Almazor, {Maria E.}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.",
year = "2022",
doi = "10.1007/978-3-031-05002-2_18",
language = "English (US)",
series = "Rare Diseases of the Immune System",
publisher = "Springer Nature",
pages = "231--242",
booktitle = "Rare Diseases of the Immune System",
address = "United States",
}